DK1015587T3 - DcR3 polypeptid, en TNFR-homolog - Google Patents

DcR3 polypeptid, en TNFR-homolog

Info

Publication number
DK1015587T3
DK1015587T3 DK98948386T DK98948386T DK1015587T3 DK 1015587 T3 DK1015587 T3 DK 1015587T3 DK 98948386 T DK98948386 T DK 98948386T DK 98948386 T DK98948386 T DK 98948386T DK 1015587 T3 DK1015587 T3 DK 1015587T3
Authority
DK
Denmark
Prior art keywords
dcr3
tnfr
homolog
dcr3 polypeptide
tnfr homolog
Prior art date
Application number
DK98948386T
Other languages
Danish (da)
English (en)
Inventor
Daniel B Tumas
William I Wood
Audrey Goddard
Avi J Ashkenazi
David Botstein
Austin L Gurney
Kyung Jin Kim
David A Lawrence
Robert Pitti
Kelly H Dodge
Margaret A Roy
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1015587T3 publication Critical patent/DK1015587T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Polymerization Catalysts (AREA)
DK98948386T 1997-09-18 1998-09-18 DcR3 polypeptid, en TNFR-homolog DK1015587T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5928897P 1997-09-18 1997-09-18
US9464098P 1998-07-30 1998-07-30
PCT/US1998/019661 WO1999014330A1 (en) 1997-09-18 1998-09-18 DcR3 POLYPEPTIDE, A TNFR HOMOLOG

Publications (1)

Publication Number Publication Date
DK1015587T3 true DK1015587T3 (da) 2008-08-25

Family

ID=26738582

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98948386T DK1015587T3 (da) 1997-09-18 1998-09-18 DcR3 polypeptid, en TNFR-homolog

Country Status (13)

Country Link
US (5) US20020065210A1 (el)
EP (1) EP1015587B1 (el)
JP (2) JP4303883B2 (el)
AT (1) ATE393222T1 (el)
AU (2) AU762959B2 (el)
CA (1) CA2303225C (el)
CY (1) CY1108175T1 (el)
DE (1) DE69839401T2 (el)
DK (1) DK1015587T3 (el)
ES (1) ES2306480T3 (el)
IL (3) IL134578A0 (el)
PT (1) PT1015587E (el)
WO (1) WO1999014330A1 (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
WO2000053755A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of tumor
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
JP2001507937A (ja) 1997-01-14 2001-06-19 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 腫瘍壊死因子レセプター６αおよび腫瘍壊死因子レセプター６β
US20040013664A1 (en) * 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
AU9376498A (en) * 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
DE69839401T2 (de) 1997-09-18 2009-05-07 Genentech Inc., San Francisco Dcr3 polypeptid, ein tnfr homolog
CA2314884A1 (en) * 1997-12-16 1999-06-24 Incyte Pharmaceuticals, Inc. Human tumor necrosis factor-r2-like proteins
DE19809978A1 (de) * 1998-03-09 1999-09-16 Basf Ag Neuer Rezeptor aus der menschlichen Lunge
BR9909328A (pt) * 1998-03-30 2000-12-12 Lilly Co Eli Aplicações terapêuticas de polipeptìdeos flint maduros (mflint) ou opg3, um membro da superfamìlia dos receptores para tnf
AU2211100A (en) * 1998-12-22 2000-07-12 Eli Lilly And Company Therapeutic applications of flint polypeptides
IL144007A0 (en) * 1999-01-15 2002-04-21 Biogen Inc Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
JP2003512020A (ja) * 1999-03-04 2003-04-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 腫瘍壊死因子レセプター６αおよび腫瘍壊死因子レセプター６β
US6965012B1 (en) 1999-03-30 2005-11-15 Eli Lilly And Company Flint polypeptide analogs
US6835814B1 (en) 1999-03-30 2004-12-28 Eli Lilly And Company Protease resistant flint analogs
AU3739400A (en) * 1999-03-30 2000-10-16 Eli Lilly And Company Flint polypeptide analogs
AU3739500A (en) * 1999-03-30 2000-10-16 Eli Lilly And Company Protease resistant flint analogs
AU2215300A (en) * 1999-06-02 2000-12-28 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
WO2001010908A1 (en) 1999-08-04 2001-02-15 Amgen Inc. Ntr3, a member of the tnf-receptor supergene family
EP1210435A1 (en) 1999-08-04 2002-06-05 Amgen Inc. Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY
AU6891800A (en) * 1999-09-10 2001-04-10 Eli Lilly And Company Flint analog compounds and formulations thereof
WO2001018041A2 (en) * 1999-09-10 2001-03-15 Eli Lilly And Company Flint proteins and formulations thereof
WO2001042463A1 (en) * 1999-12-07 2001-06-14 Eli Lilly And Company Improving stability of flint through o-linked glycosylation
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
CA2408228A1 (en) 2000-05-08 2001-11-15 Biogen, Inc. Method for promoting neovascularization
WO2002018622A2 (en) * 2000-08-25 2002-03-07 Human Genome Sciences, Inc. TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
WO2002060949A2 (en) * 2001-02-01 2002-08-08 Eli Lilly And Company Glycoforms a fas ligand inhibitory protein analog
EA011607B1 (ru) 2002-04-09 2009-04-28 Байоджен Айдек Ма Инк. Способ лечения заболеваний, связанных с tweak
US20030055221A1 (en) * 2002-05-07 2003-03-20 Jirong Lu Stability of flint through o-linked glycosylation
EP1447093A1 (en) * 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
CA2597945C (en) 2005-02-17 2016-07-12 Biogen Idec Ma Inc. Treating neurological disorders
ES2432564T3 (es) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2007076465A2 (en) * 2005-12-23 2007-07-05 Diadexus, Inc. Cln248 antibody compositions and methods of use
SI2428252T1 (sl) 2006-12-28 2015-01-30 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Nevtralizacija invazije aktivnostnih blokov cd95 v celicah glioblastoma in vivo
EP3903829B1 (en) 2009-02-13 2023-05-03 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
IN2012DN01663A (el) 2009-09-16 2015-06-05 Immunomedics Inc
EP2506881B1 (en) 2009-12-02 2024-03-06 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2014013036A1 (en) 2012-07-18 2014-01-23 Apogenix Gmbh Inhibitors of the cd95 signaling pathway for treatment of mds
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN118001422A (zh) 2012-12-13 2024-05-10 免疫医疗公司 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
CA2953567C (en) 2014-06-24 2023-09-05 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
ES2892525T3 (es) 2014-10-07 2022-02-04 Immunomedics Inc Uso neoadyuvante de conjugados anticuerpo-fármaco
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
ES2953441T3 (es) 2015-06-25 2023-11-13 Immunomedics Inc Combinación de anticuerpos anti-hla-dr o anti-Trop-2 con inhibidores de microtúbulos, inhibidores de parp, inhibidores de la cinasa de bruton o inhibidores de la fosfoinositida 3-cinasa mejora significativamente el resultado terapéutico en el cáncer
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CA3154191A1 (en) 2019-09-13 2021-03-18 Kyowa Kirin Co., Ltd. Dcr3 variant
IL293350A (en) 2019-11-27 2022-07-01 Myst Therapeutics Llc A method for producing tumor-reactive t cells using modulatory substances
JPWO2022239720A1 (el) 2021-05-10 2022-11-17

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5010182A (en) * 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
EP0397687B1 (en) 1987-12-21 1994-05-11 The University Of Toledo Agrobacterium mediated transformation of germinating plant seeds
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO2000053758A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
JP2001507937A (ja) * 1997-01-14 2001-06-19 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 腫瘍壊死因子レセプター６αおよび腫瘍壊死因子レセプター６β
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
EP1012274B2 (en) 1997-01-28 2011-06-15 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
US5885800A (en) * 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
AU9013998A (en) 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
JP2001512667A (ja) 1997-08-06 2001-08-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトオーファンレセプターｎｔｒ−１
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
DE69839401T2 (de) * 1997-09-18 2009-05-07 Genentech Inc., San Francisco Dcr3 polypeptid, ein tnfr homolog
AU1535699A (en) 1997-11-24 1999-06-15 Apotech S.A. Novel receptors opg-2
CA2314884A1 (en) 1997-12-16 1999-06-24 Incyte Pharmaceuticals, Inc. Human tumor necrosis factor-r2-like proteins
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
DE19809978A1 (de) 1998-03-09 1999-09-16 Basf Ag Neuer Rezeptor aus der menschlichen Lunge
BR9909328A (pt) 1998-03-30 2000-12-12 Lilly Co Eli Aplicações terapêuticas de polipeptìdeos flint maduros (mflint) ou opg3, um membro da superfamìlia dos receptores para tnf
CA2347835A1 (en) 1998-12-01 2000-06-08 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
JP2003512020A (ja) 1999-03-04 2003-04-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 腫瘍壊死因子レセプター６αおよび腫瘍壊死因子レセプター６β
AU3739500A (en) 1999-03-30 2000-10-16 Eli Lilly And Company Protease resistant flint analogs
AU3739400A (en) 1999-03-30 2000-10-16 Eli Lilly And Company Flint polypeptide analogs
WO2001010908A1 (en) * 1999-08-04 2001-02-15 Amgen Inc. Ntr3, a member of the tnf-receptor supergene family
TW528801B (en) 2000-12-05 2003-04-21 Anawrahta Biotech Co Ltd Monoclonal antibodies for the detection of decoy receptor 3, hybridomas producing said antibodies and uses thereof
CN102786631B (zh) * 2012-08-16 2014-05-14 京东方科技集团股份有限公司 光敏性碱可溶性树脂、其制备方法及彩色光刻胶

Also Published As

Publication number Publication date
CA2303225A1 (en) 1999-03-25
US20020061559A1 (en) 2002-05-23
US20040014176A1 (en) 2004-01-22
WO1999014330A1 (en) 1999-03-25
WO1999014330A8 (en) 1999-05-27
ES2306480T3 (es) 2008-11-01
DE69839401T2 (de) 2009-05-07
JP5153679B2 (ja) 2013-02-27
IL134578A0 (en) 2001-04-30
PT1015587E (pt) 2008-07-31
JP2001516581A (ja) 2001-10-02
US6764679B2 (en) 2004-07-20
JP2009159970A (ja) 2009-07-23
IL193919A0 (en) 2009-05-04
CY1108175T1 (el) 2014-02-12
AU762959B2 (en) 2003-07-10
US20040175791A1 (en) 2004-09-09
DE69839401D1 (en) 2008-06-05
US20020065210A1 (en) 2002-05-30
IL134578A (en) 2010-06-16
AU2003252913A1 (en) 2003-11-06
CA2303225C (en) 2015-03-31
EP1015587A1 (en) 2000-07-05
US20100080793A1 (en) 2010-04-01
EP1015587B1 (en) 2008-04-23
JP4303883B2 (ja) 2009-07-29
AU9497098A (en) 1999-04-05
ATE393222T1 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
DK1015587T3 (da) DcR3 polypeptid, en TNFR-homolog
ATE414775T1 (de) Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
ATE196164T1 (de) Gereinigte scytalidium lacassen und nukleinsäuren dafür kodierend
DE69833784D1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
DK0981618T4 (da) Anti-Apo-2-antistof
DK368588A (da) Bindingsmolekyler med en enkelt polypeptidkaede
DE60033138D1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
IL193886A (en) Antibodies that bind to ldcam sequences
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
DK1032672T3 (da) DNA19355-polypeptid, en tumornekrosefaktor-homolog
ATE358725T1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
DE69535696D1 (de) Tripeptidyl-aminopeptidase
DE69840631D1 (de) Apo-3 ligand
DK1009817T3 (da) RTD-receptor
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
FI971276A (fi) Lerk-6:ksi nimetty sytokiini
DE60026049D1 (de) POLYPEPTIDE MIT GLUCANOTRANSFERASE AKTIVITÄT UND DAFüR KODIERENDE NUKLEINSÄUREN
ATE351909T1 (de) Neue peptidfragmente zur reinigung von proteinen
DK0487229T3 (da) DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet
ATE408687T1 (de) Semaphorin polypeptide